Already Registered? Click Here

CAR T-cell therapies may be newcomers to the treatment market, but they are shaping up to be one of the most effective tools in the oncologist’s toolkit. To date, scientists have launched numerous studies aimed at improving their effectiveness, reducing side effects, and optimizing manufacturing. The ability to identify which immune cells contribute to either cancer progression or clearance is critical. Moreover, scientists need a more thorough understanding of the target specificity and biological properties of T cells that correlate with clinical outcome to help guide development and manufacturing of highly efficacious CAR-T/TCR-T cells.

In this webinar, Anthony Zamora, PhD, will discuss how single cell, multiplex analysis using proteomic barcoding and optofluidic technologies can be harnessed to better understand, characterize, and validate tumor immunogenicity and the cognate T-cell repertoire, as well as identify biologically relevant immune cell biomarkers. He will present two case studies as real-world examples.

Case Study 1: Identifying key tumor- and immune-centric parameters using streamlined single cell workflows to help guide the development and validation of engineered TCR-T cells for cancer.

Case Study 2: Single-cell analysis of bispecific CD20/CD19 CAR-T cells to identify CAR T cells with favorable anti-tumor killing potential.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.